Audit: QRS - Molybdenum for Health & Longevity
Audit conducted on 22/09/2026 18:53 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 85 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked across every surface: at-a-glance vs ER Conclusion (l. 408-412); protocol cells vs ER l. 329-333; gates vs ER l. 308-314; benefits vs ER l. 164-227; risks vs ER l. 250-294; monitoring vs ER l. 379-394. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried over: “popularized within integrative practice rather than backed by controlled trials” (action_2_sub) mirrors ER l. 330; “no form has demonstrated clinical superiority” mirrors ER l. 331. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected; e.g. at-a-glance “little sign that extra does anything useful in someone who already has enough” tracks ER l. 408 verbatim in force. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER bullet at l. 314; Key Interactions only from ER l. 308-313. No Benefit-/Risk-Modifying Factor is re-surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only ALXN1840, penicillamine, trientine, allopurinol, febuxostat, acetaminophen and MSM appear — each present in the ER for the same fact (l. 309-312). No PMIDs, NCT IDs, expert names or supplement brands carried over. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced; the Kresser attribution in ER l. 330 is correctly dropped rather than restated. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, deflationary tone toward supplementation. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (45 mcg/day requirement, 85-93% absorption, biomarker ranges) while remaining accessible. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents positions (“Best-supported position”, “integrative approach”) rather than issuing directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive or clinical-advice phrasing; monitoring cadence is stated descriptively as applying to supplemental users. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instance of “recommend”, “advise”, “should”, or “must” in QRS content. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the sheet content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; retained technical terms (eGFR, ceruloplasmin, xanthine-oxidase inhibitors) are decision-relevant and taken from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every cell is a condensed fragment; gate and tier items are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address of the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing targets a proactive optimizer weighing whether to supplement, not a patient. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol and monitoring content assumes willingness to test biomarkers and follow structured cadence. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content goes beyond general-population messaging (functional biomarker targets, integrative-practice alternative). |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Correctly signals that for this audience the actionable answer is sufficiency rather than supplementation, and flags the copper/uric-acid downside of over-supplementing. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The word “anti-aging” does not appear; the sheet frames the topic as health and longevity. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register maintained (“supplement”, “dose”, “adverse” framing); no colloquial route-of-administration or consumer-grade terms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verified against [qrs_template]: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, High/Medium/Low/Speculative, Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 distinct template variables are present; the repeatable marker_#* and qualitative_item# rows are expanded to marker_1..5 and qualitative_item_1..4. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against [qrs_template] shows only checklist-addressed spans changed; the website=”evidence_review”, website=”full_review”, website=”audit” spans, CSS and footer disclaimer are byte-identical. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; the ER supplies substantive content for every QRS surface. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reproduced verbatim: “Primary approach — dietary sufficiency”, “Targeted low-dose supplementation — integrative approach”, “Form selection” (ER l. 329-331); gate labels likewise (ER l. 308-313). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased or invented; the two time-to-effect labels are drawn from the ER wording at l. 361. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters present anywhere in the file; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to one-page budget: gate items are single clauses, tier items single lines, monitoring table five compact rows. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after <!doctype html> on line 1, and precedes all other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by “—” at line 3 and “—” at line 13; the descriptive text on line 2 precedes the opening delimiter as permitted. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element on the sheet surfaces any metadata value. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only “00:02” is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: molybdenum_2026-0802-0501_Opus_ER.md — matches the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22 — matches the version badge at the top of [qrs_prompt]. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1837 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number only; the session qualifier is correctly excluded. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: molybdenum_2026-0802-0501_Opus_QRS.html — matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting in any frontmatter value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Molybdenum for Health & Longevity - Quick Reference Sheet” — canonical_topic from ER l. 8 with & entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Molybdenum for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/22/2026 — correct MM/DD/YYYY rendering of qrs_creation_date 2026-0922. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5” — matches qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only title, creation date, review link and model; no AKA line, badge, version stamp or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Molybdenum is an essential trace mineral found in legumes, grains, dairy, and organ meats, where it switches on enzymes that clear sulfites and help process certain drugs” — kind and function stated before any verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion l. 408-412 into essentiality, dietary adequacy, copper/gout downside and the sufficiency verdict. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 69 words (counted programmatically). |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct ER passage: l. 408 (essentiality, food sources, enzymes, no benefit from extra), l. 410 (copper stripping, gout-like symptoms), l. 412 (sufficiency not supplementation). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; “trace mineral”, “sulfites”, “copper”, “gout-like symptoms” are all lay-accessible. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes appear. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No odds ratios, confidence intervals or percentages appear; the ER’s OR 0.80 and 16-fold figures are correctly omitted. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER bullet “Populations who should avoid or minimize supplemental molybdenum” in Key Interactions & Contraindications (ER l. 314). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER-named populations are represented: gout/hyperuricemia, Wilson’s disease on copper-lowering therapy, gallstones, reduced kidney function, pregnancy/breastfeeding, diagnosed copper deficiency. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the [stop_items] span (lines 571-578). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is a bare clause; no mechanistic rationale, citation or trailing dash clause survives. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers preserved and compressed: “(except under specialist direction)”, “(eGFR <60 mL/min/1.73 m²)” from ER’s longer gloss, “beyond the 50 mcg requirement”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is correctly populated, as the ER does identify populations that should avoid supplemental molybdenum. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Contraindications section is not empty (six items present). |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications bullets at l. 308-313. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All six interaction bullets carried over; the populations bullet (ER l. 314) is correctly routed to Contraindications instead and not duplicated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the [caution_items] span (lines 584-597). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity/consequence/mitigation prose stripped; the “— gout drugs” trailing clause in ER l. 310 is correctly removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved: “(tetrathiomolybdate/ALXN1840, penicillamine, trientine)”, “(allopurinol, febuxostat)”, “(sulfite-preserved foods, high-dose sulfur-amino-acid or MSM supplements)”, “(high-dose zinc)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is correctly populated, as the ER names six interactions that change how the intervention is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Key Interactions section is not empty (six items present). |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (l. 329-338). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three cells carry the ER’s primary approach (dietary sufficiency), the integrative alternative (45-150 mcg/day) and form selection — the three decision-bearing aspects. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains far more than three actionable implementation aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry substantive ER-derived content; no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER provides two distinct time-to-effect scenarios (ER l. 361); both are carried and the unused third set is handled under 11.3. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by benefit magnitude: genuine deficiency (full reversal, ER l. 168) first, already-adequate adult (no effect) second. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | The third set is emptied and hidden with style=”display: none” (lines 521-531); no placeholder or empty-state text. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used sets carry ER-derived content from Practical Considerations l. 361. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations, line 361), so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (l. 154-227). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans present and populated (lines 539-562). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier lists the ER benefit headings only, semicolon-separated; no magnitudes, mechanisms or study detail. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried; the ER’s “⚠️ Conflicted” flags and magnitude lines are dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers (high, medium, low, speculative) have items in the ER, so no span is hidden. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (l. 240-294). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans present and populated (lines 608-625). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier lists the ER risk headings only; no case details, doses or frequencies. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Parentheticals stripped — e.g. ER “Reduced fertility and growth signals (animal/observational)” appears as “reduced fertility and growth signals”. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers (high, medium, low, speculative) have items in the ER, so no span is hidden. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (l. 375-387). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All five ER biomarkers are listed: serum copper, ceruloplasmin, serum uric acid, complete blood count, plasma/serum molybdenum — with targets and rationale matching ER l. 383-387. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from ER l. 379: baseline, 8-12 weeks, then every 6-12 months, with prompt discontinuation and recheck on any abnormality. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative markers list in the ER Monitoring Protocol & Defining Success section (l. 389-394). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four ER qualitative markers are listed (lines 720-739), matching ER l. 391-394. |
Issues 22/09/2026 18:53
Pass rate 100.00%. No issues found.
Issues 22/09/2026 18:47
- 2.15 — Colloquial phrasing in lede: The At-A-Glance span at line 437 uses the consumer-grade construction “Overdoing it strips copper”, where the document’s own voice requires formal terminology for excess intake and copper depletion.
Fixes 22/09/2026 18:47
- 2.15 — Colloquial phrasing in lede: Replaced “Overdoing it strips copper” with “Excess molybdenum depletes copper” in [at_a_glance], restoring formal terminology while staying within the 70-word budget (69 words).
Issues 22/09/2026 18:41
- 2.5 / 2.6 / 2.9 — Imperative in monitoring cadence: [monitoring_cadence] (line 711) closes with “discontinue and recheck promptly if any abnormality or symptom appears”, an imperative that advises and addresses the reader directly, even though the first half of the same sentence was already recast as a neutral noun phrase.
Fixes 22/09/2026 18:41
- 2.5 / 2.6 / 2.9 — Imperative in monitoring cadence: Recast the closing clause of [monitoring_cadence] from the reader-directed imperative “discontinue and recheck promptly if any abnormality or symptom appears” to the neutral “prompt discontinuation and recheck if any abnormality or symptom appears”.